Trials / Completed
CompletedNCT05442983
A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection
A Randomized, Single-center, Single-blind, Placebo-controlled Study to Evaluate the Efficacy of PanCytoVir™ 500 mg Twice Daily and 1000 mg Twice Daily for the Treatment of Non-hospitalized Patients With COVID-19 Infection
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- TrippBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, single-center, single-blind, placebo controlled, study to evaluate efficacy of PanCytoVir™ 500 mg twice daily and 1000 mg twice daily for the treatment of non-hospitalized patients with COVID-19 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PanCytoVir™ (probenecid) | Active drug |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2022-07-12
- Primary completion
- 2022-09-07
- Completion
- 2022-10-08
- First posted
- 2022-07-05
- Last updated
- 2023-08-25
Locations
1 site across 1 country: India
Source: ClinicalTrials.gov record NCT05442983. Inclusion in this directory is not an endorsement.